BeOne Medicines is a global oncology company that discovers, develops, and sells cancer drugs. Its core product is BRUKINSA (zanubrutinib), an oral BTK inhibitor used to treat blood cancers including CLL, MCL, and WM. BRUKINSA is designed to provide continuous BTK inhibition throughout the day — a differentiated profile versus older BTK inhibitors like ibrutinib, which only achieve peak inhibition for part of the day. BRUKINSA is approved in 77 markets and generated $3.9B in FY25 sales, representing roughly three-quarters of total company revenue. BeOne's second key product is TEVIMBRA (tislelizumab), an anti-PD-1 antibody for solid tumors approved across 51 markets; it is the leading PD-1 inhibitor by coverage on China's national drug reimbursement list. BeOne also commercializes in-licensed oncology products in China from partners including Amgen and Novartis. BeOne sells directly in the U.S., EU, and China, and through distributors in 60+ other markets. BRUKINSA is a continuous-use oral therapy, meaning patients who start the drug generate recurring revenue for years. Beyond its commercial portfolio, BeOne is building a hematology franchise targeting all lines of CLL therapy: BRUKINSA as a frontline continuous option, BRUKINSA combined with its pipeline BCL2 inhibitor sonrotoclax as a fixed-duration regimen, and a BTK protein degrader (BGB-16673) for later-line patients with drug resistance. BeOne runs its own global clinical development team and manufacturing facilities, which management argues lowers trial costs and speeds development timelines.